Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors

Add time:07/12/2019    Source:sciencedirect.com

Histone deacetylase (HDAC) is a clinically validated target for antitumor therapy. In order to increase HDAC inhibition and efficiency, we developed a novel series of saccharin hydroxamic acids as potent HDAC inhibitors. Among them, compounds 11e, 11m, 11p exhibited similar or better HDACs inhibitory activity compared with the approved drug SAHA. Further biological evaluation indicated that compound 11m had potent antiproliferative activities against MDA-MB-231 and PC-3.

We also recommend Trading Suppliers and Manufacturers of N-[1,1'-biphenyl]-2-yl-4-iodobenzamide (cas 425608-77-1). Pls Click Website Link as below: cas 425608-77-1 suppliers

Prev:In vitro cytotoxicity of novel 2,5,7-tricarbo-substituted indoles derived from 2-amino-5-bromo-3-iodoacetophenone
Next:Effect of Temperature on Volumetric and Viscometric Properties of Homologous Amino Acids in Aqueous Solutions of Metformin Hydrochloride)